← Back to Screener
Gain Therapeutics, Inc. Common Stock (GANX)
Price$1.70
Value ScoreF
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-59.35%
Price vs S&P 500 (4W)-6.58%
VGM Score23.25
Market Capitalization$72.51M
All Metrics
Book Value / Share (Quarterly)$0.33
P/TBV (Annual)6.71x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.46
Price vs S&P 500 (YTD)-55.36%
Net Profit Margin (TTM)-6393.75%
EPS (TTM)$-0.60
10-Day Avg Trading Volume0.81M
EPS Excl Extra (TTM)$-0.60
EPS (Annual)$-0.89
ROI (Annual)-262.42%
Net Profit Margin (5Y Avg)-15801.64%
Cash / Share (Quarterly)$0.39
ROA (Last FY)-168.36%
EBITD / Share (TTM)$-0.54
ROE (5Y Avg)-129.19%
Operating Margin (TTM)-6506.25%
Cash Flow / Share (Annual)$-0.44
P/B Ratio5.18x
P/B Ratio (Quarterly)5.85x
Net Income / Employee (Annual)$-1,020,600
EV / Revenue (TTM)352.16x
Net Interest Coverage (TTM)-230.50x
ROA (TTM)-136.23%
EPS Incl Extra (Annual)$-0.89
Current Ratio (Annual)6.63x
Quick Ratio (Quarterly)4.51x
3-Month Avg Trading Volume0.67M
52-Week Price Return-9.81%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.33
P/S Ratio (Annual)1314.10x
Asset Turnover (Annual)0.00x
52-Week High$4.34
Operating Margin (5Y Avg)-15704.40%
EPS Excl Extra (Annual)$-0.89
CapEx CAGR (5Y)17.60%
26-Week Price Return-51.43%
Quick Ratio (Annual)6.46x
13-Week Price Return-32.27%
Total Debt / Equity (Annual)0.02x
Current Ratio (Quarterly)4.69x
Enterprise Value$56.35M
Asset Turnover (TTM)0.01x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-40210.67%
Cash / Share (Annual)$0.50
3-Month Return Std Dev97.57%
Net Income / Employee (TTM)$-1,062,000
ROE (Last FY)-278.10%
Net Interest Coverage (Annual)-22.87x
EPS Basic Excl Extra (Annual)$-0.89
Receivables Turnover (TTM)0.41x
Total Debt / Equity (Quarterly)0.03x
EPS Incl Extra (TTM)$-0.60
Receivables Turnover (Annual)0.72x
ROI (TTM)-193.85%
P/S Ratio (TTM)453.20x
Pretax Margin (5Y Avg)-15753.38%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.44
Price vs S&P 500 (52W)-34.18%
Year-to-Date Return-47.20%
5-Day Price Return-13.27%
EPS Normalized (Annual)$-0.89
ROA (5Y Avg)-86.78%
Net Profit Margin (Annual)-40354.33%
Month-to-Date Return-12.82%
Cash Flow / Share (TTM)$-1.43
EBITD / Share (Annual)$-0.89
Operating Margin (Annual)-40328.25%
LT Debt / Equity (Annual)0.02x
ROI (5Y Avg)-122.56%
LT Debt / Equity (Quarterly)0.02x
EPS Basic Excl Extra (TTM)$-0.60
P/TBV (Quarterly)5.89x
P/B Ratio (Annual)6.67x
Pretax Margin (TTM)-6375.00%
Book Value / Share (Annual)$0.44
Price vs S&P 500 (13W)-40.53%
Beta0.19x
Revenue / Share (TTM)$0.00
ROE (TTM)-201.43%
52-Week Low$1.41
vGradeF
mGradeD
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-0.13est. -0.14
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.27
4.27
4.27
4.27
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
GANXGain Therapeutics, Inc. Common Stock | F | — | D | $1.70 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Gain Therapeutics is a clinical-stage biotech company developing novel small molecule therapeutics using its proprietary Magellan platform, which identifies allosteric binding sites on disease-implicated proteins. The company's lead program, GT-02287, targets GBA1 Parkinson's disease, with a broader pipeline addressing lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. Gain operates globally across Switzerland, Spain, the United States, and Australia.